Boult Wade Tennant
Bulletins » Patentability of AI at the EPO: Is the Dust Settling?

A recent decision from the EPO’s Boards of Appeal (T 0702/20) provides a practical example of where the boundary lies in terms of patent eligibility of AI algorithms at the EPO.

The decision relates to a patent application for a neural network with fewer node connections, to reduce the number of computations and avoid overfitting. As is often the case at the EPO, the question of patent eligibility was considered as part of the inventive step (obviousness) analysis. The Application was refused by the EPO’s Examining Division as not solving a “technical” problem.

In the Appeal, the Applicant argued that the invention solved a technical problem by “providing effects within the computer related to the implementation of neural networks (storage requirements)”. They also argued that “the proposed modification in the neural network structure, in comparison with standard fully connected networks, would reduce the amount of resources required, in particular storage, and that this should be recognized as a technical effect”.

The Board of Appeal dismissed the Appeal, disagreeing for a number of reasons.

  • The claimed neural network apparatus may have a new and non-obvious structure. However, the proposed network structure, only defines a class of mathematical functions, which without a technical implementation (a “further technical use”) are always consider by the EPO as excluded matter.
  • There is nothing hardware-specific about the invention that could support a technical effect, for example, no features that “emphasise the limited resources and therefore the relevance of a small network size” or “require any adaptation of the computer”.
  • While the storage and computational requirements are indeed reduced in comparison with the fully-connected network, the functionality will also be affected, so this does not in and by itself translate to a technical effect, but rather a circumvention of the resource constraint problem.
  • The claimed learning and use of the network “to solve a classification problem or a regression problem” can use any data (i.e., including the possibility that the data is non-technical). Therefore, the outputs of the neural network do not have any implied “further technical use”.

None of the Board’s reasoning is surprising here, as it follows the well-publicised EPO Guidelines. Importantly though the Board also gave some advice on where the case went wrong, emphasizing that sufficiently specifying “the training data and the technical task addressed” is important for establishing patentability in Europe. Additionally, the Board suggested that to overcome technicality issues of this type in AI inventions, it may help if the Application demonstrates “which type of learning tasks the proposed structure may be of benefit, and to what extent”.

This reinforces that inventions relating to machine learning methods and algorithms are patentable in Europe, but it is important that the patent application identifies at least one solution to a technical problem (rather than a generic AI method). This may allow the “further technical use” to be seen (whether explicit in the claims or implied) and avoid excluded subject matter problems. This settled approach at the EPO is welcome.

Our AI Group has extensive experience with machine learning inventions. We can provide advice on patentability and assist in obtain protection in Europe and across the world. Please contact your usual Boult adviser for more details.

Relevant sectors
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Artificial Intelligence and Machine Learning
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Biotechnology
  • Antibody engineering
  • Antibody manufacture and formulation
  • Bioinformatics
  • Biosimilars
  • Drug delivery
  • Gene editing (e.g. CRISPR)
  • Genomic and molecular tools and methods
  • GM crops
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • Next generation sequencing
  • Nucleic acid synthesis
  • Personalised medicine/disease biomarkers
  • Recombinant protein production and purification
  • Stem cell therapies
  • Supplementary protection certificates (SPCs)
  • Synthetic biology
  • Therapeutic antibodies
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Women’s health products
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Communications and Networks
  • Cloud computing
  • Internet of things (IOT)
  • Oceanography, marine
  • Wired and wireless networks
Computing and Software
  • Artificial intelligence and machine learning
  • Bioinformatics
  • Blockchain and distributed ledgers
  • Communications and networks
  • Computer games
  • Data and software security, cryptography and digital rights management (DRM)
  • Data management and storage, databases and data compression
  • Digital assistants, virtual assistants and software agents
  • Fintech and adtech
  • Machine vision
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Motor capture
  • Multimedia, audio/video processing and animation
  • Natural language processing
  • Quantum computing
  • Robotic process automation
  • Search engines
  • Signal processing
  • Software applications and systems, mobile applications, user interfaces
Consumer Goods and Retail
  • Anti-counterfeit devices
  • Beauty
  • Fashion
  • Health, fitness and sport
  • Household goods
  • Luxury goods
  • Moda
  • Retail
Electronics and Electrical Devices
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Restaurants and bars
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Testing systems, control systems, signal processing
  • Travel and leisure
  • Wearable tech and human interfaces
Energy and Green Technologies
  • Biofuels
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Solar power
  • Water, oil and gas, nuclear, fusion, fission
  • Wind turbines
Food and Beverage
  • Beverages
  • Nutrition
  • Retail
Industrial Manufacturing and Processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Medical Devices and Diagnostics
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • Immuno-oncology
  • In vitro diagnostics
  • Medtech
Pharmaceuticals
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Pharmaceuticalsceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Trade Marks
  • Consumer goods
  • Cosmetics and perfumery
  • Financial services
  • Mechanical engineering
  • Mechanical products
  • Services
  • Telecommunications